Insider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Acquires 20,000 Shares of Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur bought 20,000 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The stock was acquired at an average cost of $4.92 per share, for a total transaction of $98,400.00. Following the completion of the purchase, the chief executive officer now directly owns 3,266,424 shares of the company’s stock, valued at $16,070,806.08. The trade was a 0.62 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Nuvectis Pharma Trading Up 2.0 %

Shares of Nuvectis Pharma stock opened at $5.14 on Wednesday. The company’s fifty day simple moving average is $7.07 and its two-hundred day simple moving average is $6.76. Nuvectis Pharma, Inc. has a 12-month low of $4.75 and a 12-month high of $12.10. The company has a market cap of $99.30 million, a P/E ratio of -4.43 and a beta of 0.41.

Nuvectis Pharma (NASDAQ:NVCT) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.01. During the same quarter in the previous year, the firm posted ($0.37) EPS. Analysts predict that Nuvectis Pharma, Inc. will post -1.03 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $21.00 price objective on shares of Nuvectis Pharma in a research report on Tuesday, August 6th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP lifted its stake in shares of Nuvectis Pharma by 3.7% in the 3rd quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock valued at $315,000 after purchasing an additional 1,790 shares during the period. Vanguard Group Inc. lifted its position in Nuvectis Pharma by 1.5% during the first quarter. Vanguard Group Inc. now owns 298,800 shares of the company’s stock valued at $2,450,000 after buying an additional 4,517 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Nuvectis Pharma during the 2nd quarter valued at $58,000. Nations Financial Group Inc. IA ADV purchased a new stake in shares of Nuvectis Pharma in the 3rd quarter worth about $63,000. Finally, Baxter Bros Inc. purchased a new stake in shares of Nuvectis Pharma in the 2nd quarter worth about $79,000. Hedge funds and other institutional investors own 96.77% of the company’s stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.